These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38951434)

  • 21. Treatment for women with postpartum iron deficiency anaemia.
    Jensen MCH; Holm C; Jørgensen KJ; Schroll JB
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD010861. PubMed ID: 39670550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infliximab for maintenance of medically-induced remission in Crohn's disease.
    Gordon M; Sinopoulou V; Akobeng AK; Sarian A; Moran GW
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD012609. PubMed ID: 38372447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S
    Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT.
    Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D
    Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conservative, physical and surgical interventions for managing faecal incontinence and constipation in adults with central neurological diseases.
    Todd CL; Johnson EE; Stewart F; Wallace SA; Bryant A; Woodward S; Norton C
    Cochrane Database Syst Rev; 2024 Oct; 10(10):CD002115. PubMed ID: 39470206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azathioprine for people with multiple sclerosis.
    Ridley B; Nonino F; Baldin E; Casetta I; Iuliano G; Filippini G
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD015005. PubMed ID: 39651635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Effectiveness of a Biosimilar Recombinant Growth Hormone in Adults with Growth Hormone Deficiency: Analysis of Final Data from PATRO Adults, an International Post-Marketing Surveillance Study.
    Beck-Peccoz P; Höybye C; Simsek S; Stalla G; Murray RD; Esmael A; Urosevic D; Boldea A; Zabransky M
    Drug Des Devel Ther; 2024; 18():5729-5741. PubMed ID: 39659948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
    Reece D; Imrie K; Stevens A; Smith CA;
    Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK2-V617F mutation among blood donors: A meta-analysis.
    Alsharif MH; Mansory EM; Alharazi AA; Badawi MA
    Saudi Med J; 2024 Dec; 45(12):1289-1304. PubMed ID: 39658117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interventions for preventing weight gain after smoking cessation.
    Hartmann-Boyce J; Theodoulou A; Farley A; Hajek P; Lycett D; Jones LL; Kudlek L; Heath L; Hajizadeh A; Schenkels M; Aveyard P
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD006219. PubMed ID: 34611902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
    Edahiro Y; Ohishi K; Gotoh A; Takenaka K; Shibayama H; Shimizu T; Usuki K; Shimoda K; Ito M; VanWart SA; Zagrijtschuk O; Qin A; Kawase H; Miyachi N; Sato T; Komatsu N; Kirito K
    Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
    Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
    Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis.
    Shabaninejad H; Kenny RP; Robinson T; Stoniute A; O'Keefe H; Still M; Thornton C; Pearson F; Beyer F; Meader N
    Health Technol Assess; 2024 Oct; 28(75):1-75. PubMed ID: 39487741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults.
    Brown R; Cherian K; Jones K; Wickham R; Gomez R; Sahlem G
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD015040. PubMed ID: 39092744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder.
    Kato M; Shiosakai M; Kuwahara K; Iba K; Shimada Y; Saito M; Sekine D; Aoki K; Shiomi Y; Higuchi T
    CNS Drugs; 2024 Dec; 38(12):1003-1016. PubMed ID: 39424742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
    Edwards SJ; Karner C; Jhita T; Barton S; Marceniuk G; Yiu ZZN; Wittmann M
    Health Technol Assess; 2024 Jan; 28(4):1-113. PubMed ID: 38343072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.